Clearmind Medicine Inc. (CMND) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 6-K for Q1 FY2026, filed Mar 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CMND SEC filings page.
This page shows Clearmind Medicine Inc. (CMND) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Clearmind Medicine Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Clearmind Medicine Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Clearmind Medicine Inc. reported a net loss of $3.9M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Clearmind Medicine Inc. reported -$3.9M in net income in Q1 2026. This represents a decrease of 259.7% from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Cash & Balance Sheet
Clearmind Medicine Inc. held $9.3M in cash as of Q1 2026; long-term debt is not reported for that period.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
Clearmind Medicine Inc.'s ROE was -46.8% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 9.2 percentage points from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Capital Allocation
None of these metrics is reported for Q1 2026.
CMND Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'266-K | Q4'256-K | Q3'256-K | Q2'2510-Q | Q1'256-K | Q4'2420-F | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Interest Expense | -$191K-15022.4% | N/A | $102K+117.7% | $544K+25.8% | $1K+127700.0% | N/A | -$580K-211.3% | $432K+5.1% |
| Income Tax | $4K-89.9% | N/A | $8K-80.6% | $21K-43.8% | $39K-80.5% | N/A | $43K+742.3% | $37K+296.6% |
| Net Income | -$3.9M-259.7% | N/A | N/A | N/A | -$1.1M+21.7% | N/A | -$2.1M-264.0% | -$908K+56.3% |
| Diluted Shares (Avg) | 1M+935.6% | N/A | 5M+50.1% | 5M+54.8% | 112,213-92.6% | N/A | 4M | 3M+2504.5% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted).
CMND Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'266-K | Q4'256-K | Q3'256-K | Q2'2510-Q | Q1'256-K | Q4'2420-F | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.1M+69.2% | $6.1M-16.2% | $4.0M-51.4% | $5.2M-41.4% | $6.6M-34.8% | $7.3M+21.9% | $8.2M | $8.8M |
| Current Assets | $11.0M+71.8% | $5.9M-16.1% | $3.8M-52.2% | $5.0M-42.2% | $6.4M-34.8% | $7.1M+22.3% | $8.0M | $8.7M+48.8% |
| Cash & Equivalents | $9.3M+60.1% | $3.9M-40.3% | $3.5M-54.5% | $4.5M-46.2% | $5.8M-37.7% | $6.6M+21.1% | $7.7M+99.6% | $8.3M+58.3% |
| Total Liabilities | $2.9M-22.1% | $4.9M+17.9% | $2.9M-38.2% | $2.9M-31.5% | $3.7M-26.2% | $4.1M-16.5% | $4.7M | $4.2M |
| Current Liabilities | $2.9M-22.0% | $4.9M+18.4% | $2.9M-37.9% | $2.9M-31.5% | $3.7M-25.9% | $4.1M-16.9% | $4.7M | $4.2M |
| Non-Current Liabilities | $0-100.0% | $0-100.0% | $0-100.0% | $0 | $7K-77.4% | $16K-99.7% | $26K | $0 |
| Long-Term Debt | N/A | N/A | N/A | N/A | $7K-77.4% | $16K | $26K | N/A |
| Total Equity | $8.2M+188.7% | $1.2M-61.6% | $1.1M-69.3% | $2.3M-50.5% | $2.9M-43.4% | $3.1M+216.0% | $3.5M+24.8% | $4.6M+41.9% |
| Retained Earnings | -$31.7M-26.5% | -$27.9M-16.1% | -$27.2M-17.5% | -$25.9M-23.0% | -$25.1M-24.6% | -$24.0M-28.0% | -$23.1M | -$21.0M-49.0% |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill.
CMND Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'266-K | Q4'256-K | Q3'256-K | Q2'2510-Q | Q1'256-K | Q4'2420-F | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.1M-64.8% | -$1.3M-19.4% | -$1.1M+3.7% | -$1.1M+7.9% | -$1.3M+13.4% | -$1.1M-43.0% | -$1.1M+18.1% | -$1.2M-11.5% |
| Investing Cash Flow | N/A | -$524K-49.7% | $113K+234.2% | -$200K | $69K | -$350K-933.2% | $34K | N/A |
| Financing Cash Flow | $7.4M+1732.3% | $2.2M+592.7% | -$11K-102.3% | -$10K-107.1% | $405K-92.4% | $323K-86.6% | $470K+1581.8% | $145K-95.1% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
CMND Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'266-K | Q4'256-K | Q3'256-K | Q2'2510-Q | Q1'256-K | Q4'2420-F | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -46.8%-9.2pp | N/A | N/A | N/A | -37.5%-10.4pp | N/A | -60.3%-39.6pp | -19.6%+43.9pp |
| Return on Assets | -34.6%-18.3pp | N/A | N/A | N/A | -16.3%-2.7pp | N/A | -25.6% | -10.3% |
| Current Ratio | 3.79+2.1x | 1.22-0.5x | 1.32-0.4x | 1.74-0.3x | 1.72-0.2x | 1.72+0.5x | 1.71 | 2.07 |
| Debt-to-Equity | 0.35+0.4x | 4.10+4.1x | 2.72+2.7x | 1.25+0.3x | 0.000.0x | 0.01-5.0x | 0.01 | 0.90 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Clearmind Medicine Inc. CMND | FY2025 | N/A | -$3.9M | N/A | $3.3M | — |
| 60 Degrees Pharmaceuticals, Inc. SXTP | FY2025 | $1.0M | -$7.4M | N/A | $3.9M | 57/100 |
| TITAN PHARMACEUTICAL INC TTNP | FY2024 | N/A | -$4.7M | N/A | $6.1M | — |
| Silo Pharma, Inc. SILO | FY2025 | $72K | -$4.2M | N/A | $3.0M | — |
| Pasithea Therapeutics Corp. KTTA | FY2025 | N/A | -$20.4M | N/A | $14.8M | — |
| Polyrizon Ltd. PLRZ | FY2025 | N/A | -$3.3M | N/A | $22.2M | — |
Where Clearmind Medicine Inc. Ranks
Frequently Asked Questions
Is Clearmind Medicine Inc. profitable?
No, Clearmind Medicine Inc. (CMND) reported a net income of -$3.9M in fiscal year 2025.
What is Clearmind Medicine Inc.'s return on equity (ROE)?
Clearmind Medicine Inc. (CMND) has a return on equity of -323.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Clearmind Medicine Inc.'s operating cash flow?
Clearmind Medicine Inc. (CMND) recorded an outflow of $4.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Clearmind Medicine Inc.'s total assets?
Clearmind Medicine Inc. (CMND) had $6.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Clearmind Medicine Inc.'s current ratio?
Clearmind Medicine Inc. (CMND) had a current ratio of 1.22 as of fiscal year 2025, which is considered adequate.
What is Clearmind Medicine Inc.'s debt-to-equity ratio?
Clearmind Medicine Inc. (CMND) had a debt-to-equity ratio of 4.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Clearmind Medicine Inc.'s return on assets (ROA)?
Clearmind Medicine Inc. (CMND) had a return on assets of -63.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Clearmind Medicine Inc.'s P/E ratio?
Clearmind Medicine Inc. (CMND) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.3M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Clearmind Medicine Inc.'s price-to-sales ratio?
Clearmind Medicine Inc. (CMND) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $3.3M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Clearmind Medicine Inc.'s Piotroski F-Score?
Clearmind Medicine Inc. (CMND) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Clearmind Medicine Inc.'s earnings high quality?
Clearmind Medicine Inc. (CMND) reported a net loss of $3.9M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.